Navegar por autor "Bello López, José Luis"

A phase 2 study from spanish geltamo group investigating the efficacy and safety of bendamustine as part of conditioning regimen for autologous stem-cell transplantation in patients with aggressive lymphomas: Second interim analysis

2014- Bello López, José Luis

A point score simplification for practical use of the risk stratification for splenic marginal zone lymphoma based on hemoglobin, platelet count, high LDH level and extrahilar lymphadenopathy

2013- Bello López, José Luis

A Three-Gene Expression Signature Identifies a Cluster of Patients with Short Survival in Chronic Lymphocytic Leukemia

2019- MOSQUERA ORGUEIRA, ADRIAN; Antelo Rodríguez, Beatriz; Díaz Arias, José; Díaz Varela, Nicolás; Bello López, José Luis [et al.]

A Three-Gene Expression Signature Identifies a Cluster of Patients with Short Survival in Chronic Lymphocytic Leukemia.

2019-11-07- MOSQUERA ORGUEIRA, ADRIAN; Antelo Rodríguez, Beatriz; Díaz Arias, José; Díaz Varela, Nicolás; Bello López, José Luis [et al.]

ANALYSIS OF THE EFFICACY OF PHOTOPHERESIS IN THE TREATMENT OF PATIENTS WITH REFRACTORY OR CORTICODEPENDENT EICH: EXPERIENCE OF A CENTRE

2015- Bello López, José Luis; Vilariño López, María Dolores; Villamayor Álvarez, Mercedes; Campos Pena, Alfredo

The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution

2019- MOSQUERA ORGUEIRA, ADRIAN; Antelo Rodríguez, Beatriz; Alonso Vence, Natalia; Díaz Arias, José; Díaz Varela, Nicolás; [et al.]

Bendamustin as part of conditioning regimen for autologous stem cell transplantation (ASCT) in patients with aggressive lymphomas: A phase 2 study fromspanish geltamo group

2013- Bello López, José Luis

Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group

2019- Redondo, A. M.; Valcárcel, D.; González-Rodríguez, A. P.; Suárez-Lledó, M.; Bello López, José Luis; [et al.]

BEndamustine plus rituximab in first line systemic treatment for extranodal malt lymphoma: Final results of phase ii trial of the spanish lymphoma study group (geltamo)

2013- Bello López, José Luis

Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study)

2013- Debén Ariznavarreta, Guillermo; Bello López, José Luis

Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy

2014- Constenla Figueiras, Manuel; López López, Rafael; Bello López, José Luis

DO WE STILL NEED THE ALKYLATORS AS PART OF THE UPFRONT-TREATMENT OF ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS? UPDATED FOLLOW-UP OF GEM2005MAS65 SPANISH TRIAL COMPARING VMP VS VTP AS INDUCTION

2014- Bello López, José Luis

Do we still need the alkylators as part of the upfronttreatment of elderly newly diagnosed multiple myeloma patients? Updated follow-up of GEM2005MAS65 Spanish trial comparing VMP vs VTP as induction

2014- Bello López, José Luis

First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial

2014- Bello López, José Luis

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

2014- Bello López, José Luis

Identification of new putative driver mutations and predictors of disease evolution in chronic lymphocytic leukemia

2019- MOSQUERA ORGUEIRA, ADRIAN; Antelo Rodríguez, Beatriz; Díaz Arias, José; Bello López, José Luis

Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling

2020- MOSQUERA ORGUEIRA, ADRIAN; Díaz Arias, José; Cid López, Miguel; Peleteiro Raindo, Andrés; Antelo Rodríguez, Beatriz; [et al.]

Influence of genetic polymorphisms in CYP1A2, CYP2C19, CYP3A4, GSTP1, MDR1 and PSMB5 genes in toxicity and response to induction therapy in multiple myeloma patients included in the trial of the Spanish PETHEMA/GEM 05 for newly diagnosed MM elderly patien

2011- Bello López, José Luis

Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial

2014- Bello López, José Luis

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

2012- Bello López, José Luis

Repositorio digital RUNA

Navegar por autor "Bello López, José Luis"

A phase 2 study from spanish geltamo group investigating the efficacy and safety of bendamustine as part of conditioning regimen for autologous stem-cell transplantation in patients with aggressive lymphomas: Second interim analysis ﻿

A point score simplification for practical use of the risk stratification for splenic marginal zone lymphoma based on hemoglobin, platelet count, high LDH level and extrahilar lymphadenopathy ﻿

A Three-Gene Expression Signature Identifies a Cluster of Patients with Short Survival in Chronic Lymphocytic Leukemia ﻿

A Three-Gene Expression Signature Identifies a Cluster of Patients with Short Survival in Chronic Lymphocytic Leukemia. ﻿

ANALYSIS OF THE EFFICACY OF PHOTOPHERESIS IN THE TREATMENT OF PATIENTS WITH REFRACTORY OR CORTICODEPENDENT EICH: EXPERIENCE OF A CENTRE ﻿

The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution ﻿

Bendamustin as part of conditioning regimen for autologous stem cell transplantation (ASCT) in patients with aggressive lymphomas: A phase 2 study fromspanish geltamo group ﻿

Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group ﻿

BEndamustine plus rituximab in first line systemic treatment for extranodal malt lymphoma: Final results of phase ii trial of the spanish lymphoma study group (geltamo) ﻿

Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study) ﻿

Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy ﻿

DO WE STILL NEED THE ALKYLATORS AS PART OF THE UPFRONT-TREATMENT OF ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS? UPDATED FOLLOW-UP OF GEM2005MAS65 SPANISH TRIAL COMPARING VMP VS VTP AS INDUCTION ﻿

Do we still need the alkylators as part of the upfronttreatment of elderly newly diagnosed multiple myeloma patients? Updated follow-up of GEM2005MAS65 Spanish trial comparing VMP vs VTP as induction ﻿

First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial ﻿

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? ﻿

Identification of new putative driver mutations and predictors of disease evolution in chronic lymphocytic leukemia ﻿

Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling ﻿

Influence of genetic polymorphisms in CYP1A2, CYP2C19, CYP3A4, GSTP1, MDR1 and PSMB5 genes in toxicity and response to induction therapy in multiple myeloma patients included in the trial of the Spanish PETHEMA/GEM 05 for newly diagnosed MM elderly patien ﻿

Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial ﻿

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial ﻿

A phase 2 study from spanish geltamo group investigating the efficacy and safety of bendamustine as part of conditioning regimen for autologous stem-cell transplantation in patients with aggressive lymphomas: Second interim analysis

A point score simplification for practical use of the risk stratification for splenic marginal zone lymphoma based on hemoglobin, platelet count, high LDH level and extrahilar lymphadenopathy

A Three-Gene Expression Signature Identifies a Cluster of Patients with Short Survival in Chronic Lymphocytic Leukemia

A Three-Gene Expression Signature Identifies a Cluster of Patients with Short Survival in Chronic Lymphocytic Leukemia.

ANALYSIS OF THE EFFICACY OF PHOTOPHERESIS IN THE TREATMENT OF PATIENTS WITH REFRACTORY OR CORTICODEPENDENT EICH: EXPERIENCE OF A CENTRE

The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution

Bendamustin as part of conditioning regimen for autologous stem cell transplantation (ASCT) in patients with aggressive lymphomas: A phase 2 study fromspanish geltamo group

Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group

BEndamustine plus rituximab in first line systemic treatment for extranodal malt lymphoma: Final results of phase ii trial of the spanish lymphoma study group (geltamo)

Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study)

Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy

DO WE STILL NEED THE ALKYLATORS AS PART OF THE UPFRONT-TREATMENT OF ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS? UPDATED FOLLOW-UP OF GEM2005MAS65 SPANISH TRIAL COMPARING VMP VS VTP AS INDUCTION

Do we still need the alkylators as part of the upfronttreatment of elderly newly diagnosed multiple myeloma patients? Updated follow-up of GEM2005MAS65 Spanish trial comparing VMP vs VTP as induction

First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

Identification of new putative driver mutations and predictors of disease evolution in chronic lymphocytic leukemia

Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling

Influence of genetic polymorphisms in CYP1A2, CYP2C19, CYP3A4, GSTP1, MDR1 and PSMB5 genes in toxicity and response to induction therapy in multiple myeloma patients included in the trial of the Spanish PETHEMA/GEM 05 for newly diagnosed MM elderly patien

Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial